Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
A Double-Blind Placebo Controlled Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Ovarian Tubal and Peritoneal Carcinoma
5 other identifiers
interventional
400
2 countries
46
Brief Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether giving monoclonal antibody therapy is more effective than a placebo in treating patients with ovarian epithelial, fallopian tube, or peritoneal cancer who have responded to surgery and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients with residual disease from stage III or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer following surgery and chemotherapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
46 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 1998
CompletedFirst Submitted
Initial submission to the registry
November 1, 1999
CompletedFirst Posted
Study publicly available on registry
September 13, 2004
CompletedNovember 6, 2013
May 1, 2007
November 1, 1999
November 5, 2013
Conditions
Keywords
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- AltaRexlead
Study Sites (46)
Alta Bates Comprehensive Cancer Center
Berkeley, California, 94704, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800, United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781, United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
Wilshire Oncology Medical Center
Pomona, California, 91767, United States
Stanford University School of Medicine
Stanford, California, 94305-5317, United States
University of Colorado Cancer Center
Denver, Colorado, 80262, United States
Patty Berg Cancer Center
Fort Myers, Florida, 33901, United States
University of Florida Health Science Center - Jacksonville
Jacksonville, Florida, 32209, United States
Walt Disney Memorial Cancer Institute
Orlando, Florida, 32804, United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637, United States
Saint Mary's Hospital
East Saint Louis, Illinois, 62201, United States
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
Alton Ochsner Medical Foundation Hospital
New Orleans, Louisiana, 70121, United States
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201, United States
New England Medical Center Hospital
Boston, Massachusetts, 02111, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
University of Minnesota Medical School
Minneapolis, Minnesota, 55455, United States
Ellis Fischel Cancer Center
Columbia, Missouri, 65203, United States
North Shore University Hospital
Manhasset, New York, 11030, United States
State University of New York - Upstate Medical University
Syracuse, New York, 13210, United States
University of Oklahoma
Oklahoma City, Oklahoma, 73190, United States
Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303, United States
Baptist Regional Cancer Center - Knoxville
Knoxville, Tennessee, 37901, United States
University of Texas Southwestern Medical School
Dallas, Texas, 75235-9032, United States
U.S. Oncology
Houston, Texas, 77060, United States
Cancer Center, University of Virginia HSC
Charlottesville, Virginia, 22908, United States
Swedish Hospital Tumor Institute
Seattle, Washington, 98104, United States
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2, Canada
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
British Columbia Cancer Agency - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
Manitoba Cancer Treatment and Research Foundation
Winnipeg, Manitoba, R3E 0V9, Canada
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2, Canada
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7, Canada
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1, Canada
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6, Canada
Credit Valley Hospital
Mississauga, Ontario, L5M 2N1, Canada
Ottawa Regional Cancer Center - General Division
Ottawa, Ontario, K1H 8L6, Canada
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
Centre Universitaire de Sante de l'Estrie
Fleurimont, Quebec, J1H 5N4, Canada
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2W-W1T8, Canada
Jewish General Hospital - Montreal
Montreal, Quebec, H3T 1E2, Canada
Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec
Québec, Quebec, G1R 2J6, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jonathan S. Berek, MD
Jonsson Comprehensive Cancer Center